New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:10 EDTPTLAPortola announces andexanet alfa, enoxaparin 'positive' Phase 2 data
Portola Pharmaceuticals announced that a Phase 2 proof-of-concept study in healthy volunteers demonstrated that andexanet alfa immediately reversed the anticoagulation activity of enoxaparin. Andexanet alfa was well tolerated with no serious adverse events reported. Detailed data will be presented during both oral and poster sessions at the 60th Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis. Portola is developing andexanet alfa to reverse the anticoagulation activity of Factor Xa inhibitor-treated patients who are experiencing a major bleeding episode or who require emergency surgery. Andexanet alfa was well tolerated with no thrombotic events or serious adverse events reported. No antibodies to andexanet alfa, Factor Xa or Factor X were observed.
News For PTLA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
16:11 EDTPTLAPortola Pharmaceuticals enters into supply agreement for andexanet alfa
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use